Breaking News on Contract Research, Manufacturing & Clinical Trials

Exclusive interview

Data, patients and payers key to “New Health” success, says Quintiles

By Gareth Macdonald, 13-Jul-2010

Related topics: Data management, Phase I-II, Phase III-IV, Clinical Development, Clinical evolution

Quintiles’ Jay Norman tells Outsourcing-pharma that data sharing and patient and payer concerns will drive drug industry competition and clinical development decisions accord to new research.

The contract research organisation (CRO) completed its “New Health” report analysing the drug development industry’s evolution during what Norman described as a “period of constant change.”

He predicted that the tough pharmaceutical market is going to get tougher as industry adapts to managing relationships with new “constellation” of patient, payer and policy making stakeholders.

Norman also revealed that the focus of drug industry competition seems to be shifting away from capital expenditure and science to data and analytics, particularly when companies are deciding which drugs to take into clinical development and when.

“We expect to see increased information exchange between pharma competitors and payers…to share data around why products fail and what seems to be working,” he explained, adding that while pharma focuses on trials and getting to market, patients and payers are look at quality of life benefits post market.

Copyright - Unless otherwise stated all contents of this web site are © 2012 - William Reed Business Media SAS - All Rights Reserved - For permission to reproduce any contents of this web site, please email our Syndication department copyright@wrbm.com - Full details for the use of materials on this site can be found in the Terms & Conditions

© 2012 - William Reed Business Media SAS - All rights reserved.